Smith & Nephew/£SN
Smith & Nephew jumps after reporting H1 profit up 11.2% and announcing a $500m share buyback.
7 hours ago·Lightyear AI
07:00
03:10
23:15
19:25
15:30
1D1W1MYTD1Y5YMAX
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Ticker
£SN
Sector
Primary listing
LSE
Employees
17,349
Headquarters
Website
Smith & Nephew Metrics
BasicAdvanced
£10B
32.73
£0.35
0.63
£0.29
2.47%
Price and volume
Market cap
£10B
Beta
0.63
52-week high
£12.00
52-week low
£9.11
Average daily volume
1.8M
Dividend rate
£0.29
Financial strength
Current ratio
2.888
Quick ratio
1.329
Long term debt to equity
61.88
Total debt to equity
63.077
Dividend payout ratio (TTM)
79.37%
Interest coverage (TTM)
4.53%
Profitability
EBITDA (TTM)
931.275
Gross margin (TTM)
70.21%
Net profit margin (TTM)
7.09%
Operating margin (TTM)
11.31%
Effective tax rate (TTM)
17.27%
Revenue per employee (TTM)
£248,440
Management effectiveness
Return on assets (TTM)
5.44%
Return on equity (TTM)
7.86%
Valuation
Price to earnings (TTM)
32.727
Price to revenue (TTM)
2.311
Price to book
1.91
Price to tangible book (TTM)
8.34
Price to free cash flow (TTM)
22.159
Free cash flow yield (TTM)
4.51%
Free cash flow per share (TTM)
0.523
Dividend yield (TTM)
2.47%
Growth
Revenue change (TTM)
4.70%
Earnings per share change (TTM)
56.15%
3-year revenue growth (CAGR)
3.69%
10-year revenue growth (CAGR)
2.33%
3-year earnings per share growth (CAGR)
-7.66%
10-year earnings per share growth (CAGR)
-1.68%
10-year dividend per share growth (CAGR)
2.39%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Bulls say / Bears say
Smith & Nephew's strategic partnership with Standard Health to establish the UK's first dedicated Orthopaedic Ambulatory Surgery Centre positions the company to capitalize on the growing shift toward outpatient orthopedic procedures, potentially enhancing revenue and market share. (nasdaq.com)
The company's first-quarter 2025 results showed a 3.1% year-over-year revenue growth, indicating operational improvements and sustained demand for its products. (massdevice.com)
Smith & Nephew's stock reached a 52-week high of $31.25 in September 2024, reflecting strong investor confidence and positive market sentiment. (investing.com)
JPMorgan Chase & Co. significantly reduced its position in Smith & Nephew by 90.5% during the third quarter, which may indicate concerns about the company's future performance. (defenseworld.net)
Several analysts, including UBS Group and HSBC, downgraded Smith & Nephew's stock from 'buy' to 'hold' in early 2025, suggesting a more cautious outlook on the company's growth prospects. (defenseworld.net)
The company's exposure to foreign exchange headwinds and market volatility, as noted in their first-quarter 2025 report, could impact profitability and financial stability. (massdevice.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
Oct2
Smith & Nephew
Dividend·Ex-dividend
Nov7
Smith & Nephew
Dividend·Payment
$0.15Per share
FAQs
What’s the current market cap for Smith & Nephew stock?
Smith & Nephew (SN) has a market cap of £10B as of August 05, 2025.
What is the P/E ratio for Smith & Nephew stock?
The price to earnings (P/E) ratio for Smith & Nephew (SN) stock is 32.73 as of August 05, 2025.
Does Smith & Nephew stock pay dividends?
Yes, the Smith & Nephew (SN) stock pays dividends to shareholders. As of August 05, 2025, the dividend rate is £0.2858 and the yield is 2.47%. Smith & Nephew has a payout ratio of 79.37% on a trailing twelve-month basis.
When is the next Smith & Nephew dividend payment date?
The next Smith & Nephew (SN) dividend payment date is unconfirmed.
What is the beta indicator for Smith & Nephew?
Smith & Nephew (SN) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.